FindTrial
Sign In

TAK-700

DRUG6 trials

Sponsors

Millennium Pharmaceuticals, Inc., Radiation Therapy Oncology Group, SWOG Cancer Research Network, University of Wisconsin, Madison

Conditions

Prostate CancerProstatic Neoplasms

Phase 1

Safety Study of TAK-700 in Subjects With Prostate Cancer.
CompletedNCT00569153
Millennium Pharmaceuticals, Inc.Prostatic Neoplasms
Start: 2008-04-30End: 2013-02-28Updated: 2016-04-04
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
CompletedNCT01084655
Millennium Pharmaceuticals, Inc.Prostate Cancer
Start: 2010-07-31End: 2016-03-31Updated: 2019-07-30

Phase 2

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
CompletedNCT01046916
Millennium Pharmaceuticals, Inc.Prostate Cancer
Start: 2010-05-31End: 2013-03-31Updated: 2016-04-04
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
TerminatedNCT01816048
University of Wisconsin, MadisonProstate Cancer, Prostatic Neoplasms
Start: 2013-05-31End: 2016-11-30Updated: 2019-12-09

Phase 3

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
CompletedNCT01546987
Radiation Therapy Oncology GroupProstate Cancer
Start: 2012-05-01End: 2025-09-04Updated: 2026-03-06
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
CompletedNCT01809691
SWOG Cancer Research NetworkProstate Cancer
Start: 2013-03-08End: 2025-09-09Updated: 2025-12-31

Related Papers

Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Journal of Clinical Oncology2025-05-28
Time to metastasis after prostatectomy (TTM) and survival outcomes in patients (pts) with metachronous metastatic hormone-sensitive prostate cancer (mHSPC): A secondary analysis of the SWOG 1216 phase 3 trial.
Journal of Clinical Oncology2025-02-10
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
JAMA Network Open2024-07-096 citations
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.
Journal of Clinical Oncology2024-06-01
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
2024-02-29
Baseline bone pain as a prognostic marker for survival for men with metastatic hormone-sensitive prostate cancer (mHSPC): Patient-level analysis of SWOG 1216 trial.
Journal of Clinical Oncology2024-01-29
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer
JAMA Network Open2023-08-019 citations
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
Journal of Clinical Oncology2023-06-012 citations
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.
Journal of Clinical Oncology2023-06-01
Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.
Journal of Clinical Oncology2022-06-012 citations
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Journal of Clinical Oncology2021-05-207 citations
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.
Journal of Clinical Oncology2020-05-20
Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel
Annals of Oncology2018-10-01
Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology2016-05-206 citations
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).
Journal of Clinical Oncology2014-05-20